Education
About Us
Working with TipRanks
Follow Us
Tyra Bioscience (TYRA)
NASDAQ:TYRA
Total Valuation
Tyra Bioscience has a market cap or net worth of $839.54M. The enterprise value is $279.65M.
Market Cap$839.54M
Enterprise Value$279.65M
Share Statistics
Tyra Bioscience has 53,372,097 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding53,372,097
Owned by Insiders50.21%
Owned by Institutions6.82%
Financial Efficiency
Tyra Bioscience’s return on equity (ROE) is -0.25 and return on invested capital (ROIC) is -29.78%.
Return on Equity (ROE)-0.25
Return on Assets (ROA)-0.24
Return on Invested Capital (ROIC)-29.78%
Return on Capital Employed (ROCE)-0.30
Revenue Per Employee0.00
Profits Per Employee-1.44M
Employee Count60
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Tyra Bioscience is ―. Tyra Bioscience’s PEG ratio is 1.35.
PE Ratio―
PS Ratio0.00
PB Ratio2.32
Price to Fair Value2.32
Price to FCF-11.29
Price to Operating Cash Flow-10.48
PEG Ratio1.35
Income Statement
In the last 12 months, Tyra Bioscience had revenue of 0.00 and earned -86.48M in profits. Earnings per share was -1.51.
Revenue0.00
Gross Profit0.00
Operating Income-104.18M
Pretax Income-86.48M
Net Income-86.48M
EBITDA-103.66M
Earnings Per Share (EPS)-1.51
Cash Flow
In the last 12 months, operating cash flow was -91.11M and capital expenditures -90.00K, giving a free cash flow of -91.20M billion.
Operating Cash Flow-91.11M
Free Cash Flow-91.20M
Free Cash Flow per Share-1.71
Dividends & Yields
Tyra Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.82
52-Week Price Change2.21%
50-Day Moving Average13.88
200-Day Moving Average11.39
Relative Strength Index (RSI)62.01
Average Volume (3m)179.05K
Important Dates
Tyra Bioscience upcoming earnings date is Mar 25, 2026, After Close (Confirmed).
Last Earnings DateNov 5, 2025
Next Earnings DateMar 25, 2026
Ex-Dividend Date―
Financial Position
Tyra Bioscience as a current ratio of 23.81, with Debt / Equity ratio of 1.99%
Current Ratio23.81
Quick Ratio23.81
Debt to Market Cap<0.01
Net Debt to EBITDA1.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Tyra Bioscience has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Tyra Bioscience EV to EBITDA ratio is -8.25, with an EV/FCF ratio of -10.07.
EV to Sales0.00
EV to EBITDA-8.25
EV to Free Cash Flow-10.07
EV to Operating Cash Flow-10.17
Balance Sheet
Tyra Bioscience has $274.92M in cash and marketable securities with $5.92M in debt, giving a net cash position of $269.00M billion.
Cash & Marketable Securities$274.92M
Total Debt$5.92M
Net Cash$269.00M
Net Cash Per Share$5.04
Tangible Book Value Per Share$6.00
Margins
Gross margin is -32.66%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-32.66%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Tyra Bioscience is $32.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$32.40
Price Target Upside105.98% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast-17.01%